Skip to main content
. Author manuscript; available in PMC: 2013 Jul 12.
Published in final edited form as: J Immunother. 2011 Sep;34(7):556–567. doi: 10.1097/CJI.0b013e3182280db1

TABLE 7.

Association Between Immune Response and Clinical Outcome

Outcome* Immune Responders† Percent T cells at Baseline‡ Median (Range)
Peak percent T Cells After Immunization§ Median (Range)
Patients With Coinduction of T Cells at End of Cycle 2||
PRAME PSMA PRAME PSMA PRAME & PSMA
Rapid tumor progression 7/14 0.17 (0–0.62) 0.19 (0–0.43) 0.23 (0.08–1.54) 0.22 (0.13–1.29) 1/14
Disease control 6/7 0.07 (0–0.48) 0.05 (0–0.44) 0.43 (0.16–0.84) 0.51 (0.16–1.67) 4/7
*

Patients were categorized retrospectively in 2 clinical outcome groups: with SD for 6 months or longer (disease control), or with rapidly progressing disease.

†

Immune responders according to preset criteria/total number of patients in that clinical outcome group. P value of 2-tailed Fisher exact test comparing the 2 groups was 0.1736.

‡

Percent tetramer+ CD8+ T cells in peripheral blood, at baseline.

§

Percent tetramer+ CD8+ T cells in peripheral blood, after immunization.

||

Number of patients who showed measurable immune responses against both antigens at the completion of second cycle, per total number of patients in that clinical outcome group. P value of 2-tailed Fisher exact test comparing the 2 groups was 0.0251.